Download PDF
Int J Angiol 2022; 31(04): 251-259
DOI: 10.1055/s-0042-1758357
Invited Article

Pathophysiology and Management of Heart Failure in the Elderly

Nakeya Dewaswala
1   Department of Cardiovascular Diseases, University of Kentucky, Lexington, Kentucky
,
Vinayak Mishra 
2   Grant Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India
,
Huzefa Bhopalwala
3   Department of Internal Medicine, Appalachian Regional Healthcare, Whitesburg, Kentucky
,
Abdul Khan Minhas
4   Department of Internal Medicine, Forrest General Hospital, Hattiesburg, Mississippi
,
Suresh Keshavamurthy
5   Department of Surgery, University of Kentucky College of Medicine, Lexington, Kentucky
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The population of elderly adults is increasing globally. It has been projected that the population of adults aged 65 years will increase by approximately 80% by 2050 in the United States. Similarly, the elderly population is rising in other countries; a notable example being Japan where approximately 30% of the population are aged above 65 years. The pathophysiology and management of heart failure (HF) in this age group tend to have more intricacies than in younger age groups owing to the presence of multiple comorbidities. The normal aging biology includes progressive disruption at cellular and genetic levels and changes in molecular signaling and mechanical activities that contribute to myocardial abnormalities. Older adults with HF secondary to ischemic or valvular heart disease may benefit from surgical therapy, valve replacement or repair for valvular heart disease and coronary artery bypass grafting for coronary artery disease. While referring these patients for surgery, patient and family expectations and life expectations should be taken into account. In this review, we will cover the pathophysiology and the management of HF in the elderly, specifically discussing important geriatric domains such as frailty, cognitive impairment, delirium, polypharmacy, and multimorbidity.

Keywords

cardiac output - heart failure - elderly - myocardium - frailty - polypharmacy - cardiac transplantation


Publication History

Article published online:
11 November 2022

© 2022. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 An Aging Nation: The Older Population in the United States [Internet]. [cited 2022 May 17]. Accessed October 15, 2022 at: https://www.census.gov/library/publications/2014/demo/p25-1140.html
    PubMed
  • 2 Dewaswala N, Bhopalwala H, Shikari S. et al. Gender-based differences in heart transplantation rates. J Heart Lung Transplant 2022; 41 (04) S211
    CrossrefPubMedGoogle Scholar
  • 3 Minhas AMK, Mahmood Shah SM, Shahid I. et al. Utilization of implantable cardioverter-defibrillators in patients with heart transplant (from National Inpatient Sample Database). Am J Cardiol 2022; 175: 65-71
    CrossrefPubMedGoogle Scholar
  • 4 Khan Minhas AM, Bhopalwala H, Dewaswala N. et al. Comparison of outcomes in hospitalizations for heart transplant with and without obesity: analysis of national inpatient sample 2004–2014. J Am Coll Cardiol 2021; 77 (18) 649
    CrossrefPubMedGoogle Scholar
  • 5 Noor A, Shikari-Dossaji S, Dewaswala N. et al. Impact of COVID-19 vaccination after orthotopic heart transplantation. J Heart Lung Transplant 2022; 41 (04) S325
    CrossrefPubMedGoogle Scholar
  • 6 Bhopalwala H, Akbar A, Dewaswala N. et al. Outcomes of heart failure in COVID-19 patients: an Appalachian experience. Cardiol Res 2022; 13 (03) 162-171
    CrossrefPubMedGoogle Scholar
  • 7 Vallabhajosyula S, Bhopalwala HM, Sundaragiri PR. et al. Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: an 18-year study. Am Heart J 2022; 244: 54-65
    CrossrefPubMedGoogle Scholar
  • 8 Vallabhajosyula S, Dewaswala N, Sundaragiri PR. et al. Cardiogenic shock complicating ST-segment elevation myocardial infarction: an 18-year analysis of temporal trends, epidemiology, management, and outcomes. Shock 2022; 57 (03) 360-369
    CrossrefPubMedGoogle Scholar
  • 9 Lakatta EG. So! What's aging? Is cardiovascular aging a disease?. J Mol Cell Cardiol 2015; 83: 1-13
    CrossrefPubMedGoogle Scholar
  • 10 Domanski MJ, Tian X, Wu CO. et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol 2020; 76 (13) 1507-1516
    CrossrefPubMedGoogle Scholar
  • 11 Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol 2017; 69 (15) 1952-1967
    CrossrefPubMedGoogle Scholar
  • 12 Fleg JL, Strait J. Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease. Heart Fail Rev 2012; 17 (4-5): 545-554
    CrossrefPubMedGoogle Scholar
  • 13 Minhas AMK, Bhopalwala HM, Dewaswala N. et al. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. Curr Probl Cardiol 2022; (e-pub ahead of print) DOI: 10.1016/j.cpcardiol.2022.101199.
    CrossrefPubMedGoogle Scholar
  • 14 Bhopalwala H, Dewaswala N, Kolagatla S. et al. Predictors of mortality for patients with COVID-19 in the rural Appalachian region. Int J Gen Med 2022; 15: 2207-2214
    CrossrefPubMedGoogle Scholar
  • 15 Velagaleti RS, Gona P, Pencina MJ. et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. Am J Cardiol 2014; 113 (01) 117-122
    CrossrefPubMedGoogle Scholar
  • 16 Tanoue MT, Kjeldsen SE, Devereux RB, Okin PM. Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy. Blood Press 2016; 25 (06) 364-372
    CrossrefPubMedGoogle Scholar
  • 17 Uchmanowicz I, Nessler J, Gobbens R. et al. Coexisting frailty with heart failure. Front Physiol 2019; 10: 791
    CrossrefPubMedGoogle Scholar
  • 18 Fried LP, Tangen CM, Walston J. et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56 (03) M146-M156
    CrossrefPubMedGoogle Scholar
  • 19 Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013; 381 (9868): 752-762
    CrossrefPubMedGoogle Scholar
  • 20 Afilalo J, Alexander KP, Mack MJ. et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014; 63 (08) 747-762
    CrossrefPubMedGoogle Scholar
  • 21 Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018; 15 (09) 505-522
    CrossrefPubMedGoogle Scholar
  • 22 Fabbri E, An Y, Zoli M. et al. Aging and the burden of multimorbidity: associations with inflammatory and anabolic hormonal biomarkers. J Gerontol A Biol Sci Med Sci 2015; 70 (01) 63-70
    CrossrefPubMedGoogle Scholar
  • 23 Schaap LA, Pluijm SMF, Deeg DJH. et al; Health ABC Study. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009; 64 (11) 1183-1189
    CrossrefPubMedGoogle Scholar
  • 24 Soysal P, Arik F, Smith L, Jackson SE, Isik AT. Inflammation, frailty and cardiovascular disease. Adv Exp Med Biol 2020; 1216: 55-64
    PubMedGoogle Scholar
  • 25 Sarwar N, Butterworth AS, Freitag DF. et al; IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379 (9822): 1205-1213
    CrossrefPubMedGoogle Scholar
  • 26 Forman DE, Alexander KP. Frailty: a vital sign for older adults with cardiovascular disease. Can J Cardiol 2016; 32 (09) 1082-1087
    CrossrefPubMedGoogle Scholar
  • 27 Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med 2013; 29 (04) 737-752
    CrossrefPubMedGoogle Scholar
  • 28 Sandilyan MB, Dening T. Brain function, disease and dementia. Nurs Stand 2015; 29 (39) 36-42
    CrossrefPubMedGoogle Scholar
  • 29 Ganguli M, Snitz BE, Saxton JA. et al. Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 2011; 68 (06) 761-767
    CrossrefPubMedGoogle Scholar
  • 30 Justin BN, Turek M, Hakim AM. Heart disease as a risk factor for dementia. Clin Epidemiol 2013; 5: 135-145
    PubMedGoogle Scholar
  • 31 Alves TCTF, Rays J, Fráguas Jr R. et al. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging 2005; 15 (02) 150-156
    PubMedGoogle Scholar
  • 32 Jefferson AL, Poppas A, Paul RH, Cohen RA. Systemic hypoperfusion is associated with executive dysfunction in geriatric cardiac patients. Neurobiol Aging 2007; 28 (03) 477-483
    CrossrefPubMedGoogle Scholar
  • 33 Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54 (19) 1747-1762
    CrossrefPubMedGoogle Scholar
  • 34 Gruhn N, Larsen FS, Boesgaard S. et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001; 32 (11) 2530-2533
    CrossrefPubMedGoogle Scholar
  • 35 Jefferson AL, Himali JJ, Beiser AS. et al. Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation 2010; 122 (07) 690-697
    CrossrefPubMedGoogle Scholar
  • 36 Polidori MC, Mariani E, Mecocci P, Nelles G. Congestive heart failure and Alzheimer's disease. Neurol Res 2006; 28 (06) 588-594
    CrossrefPubMedGoogle Scholar
  • 37 Trojano L, Antonelli Incalzi R, Acanfora D, Picone C, Mecocci P, Rengo F. Congestive Heart Failure Italian Study Investigators. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol 2003; 250 (12) 1456-1463
    CrossrefPubMedGoogle Scholar
  • 38 Beer C, Ebenezer E, Fenner S. et al. Contributors to cognitive impairment in congestive heart failure: a pilot case-control study. Intern Med J 2009; 39 (09) 600-605
    CrossrefPubMedGoogle Scholar
  • 39 Vuong JT, Jacob SA, Alexander KM. et al. Mortality from heart failure and dementia in the United States: CDC WONDER 1999-2016. J Card Fail 2019; 25 (02) 125-129
    CrossrefPubMedGoogle Scholar
  • 40 Ramanathan R, Krishnan AM, Tandon V, Stringer B, Balakumaran K. Healthcare disparities in dementia patients admitted with CHF exacerbation: nis database analysis. Chest 2019; 156 (04) A289
    CrossrefPubMedGoogle Scholar
  • 41 Vuong JT, Akintoye E, Kim S, Desai AS, Dorbala S. Effect of concurrent dementia on heart failure hospital outcomes: Nationwide Inpatient Sample (2007-2014). J Card Fail 2021; 27 (02) 258-260
    CrossrefPubMedGoogle Scholar
  • 42 Ritt M, Ritt JI, Sieber CC, Gaßmann K-G. Comparing the predictive accuracy of frailty, comorbidity, and disability for mortality: a 1-year follow-up in patients hospitalized in geriatric wards. Clin Interv Aging 2017; 12: 293-304
    CrossrefPubMedGoogle Scholar
  • 43 Essomba MJN, Atsa D, Noah DZ. et al. Geriatric syndromes in an urban elderly population in Cameroon: a focus on disability, sarcopenia and cognitive impairment. Pan Afr Med J 2020; 37: 229
    PubMedGoogle Scholar
  • 44 Krumholz HM. Post-hospital syndrome—an acquired, transient condition of generalized risk. N Engl J Med 2013; 368 (02) 100-102
    CrossrefPubMedGoogle Scholar
  • 45 McNeil JJ, Woods RL, Nelson MR. et al; ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018; 379 (16) 1499-1508
    CrossrefPubMedGoogle Scholar
  • 46 Chaudhry SI, McAvay G, Ning Y, Allore HG, Newman AB, Gill TM. Risk factors for onset of disability among older persons newly diagnosed with heart failure: the Cardiovascular Health Study. J Card Fail 2011; 17 (09) 764-770
    CrossrefPubMedGoogle Scholar
  • 47 Henriques A, Araújo C, Viana M. et al. Disability-adjusted life years lost due to ischemic heart disease in mainland Portugal, 2013. Rev Port Cardiol 2017; 36 (04) 273-281
    CrossrefPubMedGoogle Scholar
  • 48 Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011; 124 (02) 136-143
    CrossrefPubMedGoogle Scholar
  • 49 Fiuzat M, Lowy N, Stockbridge N. et al. Endpoints in heart failure drug development: history and future. JACC Heart Fail 2020; 8 (06) 429-440
    PubMedGoogle Scholar
  • 50 Mastromarino V, Casenghi M, Testa M. et al. Polypharmacy in heart failure patients. Curr Heart Fail Rep 2014; 11 (02) 212-219
    CrossrefPubMedGoogle Scholar
  • 51 Schwartz JB, Schmader KE, Hanlon JT. et al. Pharmacotherapy in older adults with cardiovascular disease: report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop. J Am Geriatr Soc 2019; 67 (02) 371-380
    CrossrefPubMedGoogle Scholar
  • 52 Allen LA, Fonarow GC, Liang L. et al; American Heart Association's Get With The Guidelines Heart Failure (GWTG-HF) Investigators. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation 2015; 132 (14) 1347-1353
    CrossrefPubMedGoogle Scholar
  • 53 Reed BN, Rodgers JE, Sueta CA. Polypharmacy in heart failure: drugs to use and avoid. Heart Fail Clin 2014; 10 (04) 577-590
    CrossrefPubMedGoogle Scholar
  • 54 Khan MS, Segar MW, Usman MS. et al. Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT Trial. JACC Heart Fail 2022; 10 (04) 266-275
    CrossrefPubMedGoogle Scholar
  • 55 Unlu O, Levitan EB, Reshetnyak E. et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail 2020; 13 (11) e006977
    CrossrefPubMedGoogle Scholar
  • 56 Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 57 Jokanovic N, Wang KN, Dooley MJ. et al. Prioritizing interventions to manage polypharmacy in Australian aged care facilities. Res Social Adm Pharm 2017; 13 (03) 564-574
    CrossrefPubMedGoogle Scholar
  • 58 Freeland KN, Thompson AN, Zhao Y, Leal JE, Mauldin PD, Moran WP. Medication use and associated risk of falling in a geriatric outpatient population. Ann Pharmacother 2012; 46 (09) 1188-1192
    CrossrefPubMedGoogle Scholar
  • 59 Gorodeski EZ, Goyal P, Hummel SL. et al; Geriatric Cardiology Section Leadership Council, American College of Cardiology. Domain management approach to heart failure in the geriatric patient: present and future. J Am Coll Cardiol 2018; 71 (17) 1921-1936
    CrossrefPubMedGoogle Scholar
  • 60 Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?. Clin Sci (Lond) 2008; 114 (03) 221-230
    CrossrefPubMedGoogle Scholar
  • 61 García-García A, Alvarez-Sala-Walther LA, Lee H-Y, Sierra C, Pascual-Figal D, Camafort M. Is there sufficient evidence to justify changes in dietary habits in heart failure patients? A systematic review. Korean J Intern Med (Korean Assoc Intern Med) 2022; 37 (01) 37-47
    PubMedGoogle Scholar
  • 62 Yancy CW, Jessup M, Bozkurt B. et al; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16) e147-e239
    PubMedGoogle Scholar
  • 63 Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs in patients > or = 75 years of age. Am J Cardiol 1996; 78 (06) 675-677
    CrossrefPubMedGoogle Scholar
  • 64 Edwards DG, Schofield RS, Lennon SL, Pierce GL, Nichols WW, Braith RW. Effect of exercise training on endothelial function in men with coronary artery disease. Am J Cardiol 2004; 93 (05) 617-620
    CrossrefPubMedGoogle Scholar
  • 65 Taty Zau JF, Costa Zeferino R, Sandrine Mota N. et al. Exercise through a cardiac rehabilitation program attenuates oxidative stress in patients submitted to coronary artery bypass grafting. Redox Rep 2018; 23 (01) 94-99
    CrossrefPubMedGoogle Scholar
  • 66 Forman DE, Sanderson BK, Josephson RA, Raikhelkar J, Bittner V. American College of Cardiology's Prevention of Cardiovascular Disease Section. Heart failure as a newly approved diagnosis for cardiac rehabilitation: challenges and opportunities. J Am Coll Cardiol 2015; 65 (24) 2652-2659
    CrossrefPubMedGoogle Scholar
  • 67 Davies EJ, Moxham T, Rees K. et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2010; (04) CD003331
    PubMedGoogle Scholar
  • 68 O'Connor CM, Whellan DJ, Lee KL. et al; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301 (14) 1439-1450
    CrossrefPubMedGoogle Scholar
  • 69 Long L, Mordi IR, Bridges C. et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019; 1: CD003331
    PubMedGoogle Scholar
  • 70 Murad K, Goff Jr DC, Morgan TM. et al. Burden of comorbidities and functional and cognitive impairments in elderly patients at the initial diagnosis of heart failure and their impact on total mortality: the cardiovascular health study. JACC Heart Fail 2015; 3 (07) 542-550
    CrossrefPubMedGoogle Scholar
  • 71 Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail 2004; 6 (02) 235-243
    CrossrefPubMedGoogle Scholar
  • 72 Pitt B, Pfeffer MA, Assmann SF. et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370 (15) 1383-1392
    CrossrefPubMedGoogle Scholar
  • 73 Laufer-Perl M, Sadon S, Zahler D. et al. Repetitive milrinone therapy in ambulatory advanced heart failure patients. Clin Cardiol 2022; 45 (05) 488-494
    CrossrefPubMedGoogle Scholar
  • 74 Heidenreich PA, Bozkurt B, Aguilar D. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 145 (18) e895-e1032
    PubMedGoogle Scholar
  • 75 Cleland JGF, Bunting KV, Flather MD. et al; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39 (01) 26-35
    CrossrefPubMedGoogle Scholar
  • 76 Bristow MR, Gilbert EM, Abraham WT. et al; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94 (11) 2807-2816
    CrossrefPubMedGoogle Scholar
  • 77 Hjalmarson A, Goldstein S, Fagerberg B. et al; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283 (10) 1295-1302
    CrossrefPubMedGoogle Scholar
  • 78 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomised trial. Lancet 1999; 353 (9146): 9-13
    CrossrefPubMedGoogle Scholar
  • 79 McMurray JJV, Packer M, Desai AS. et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371 (11) 993-1004
    CrossrefPubMedGoogle Scholar
  • 80 Kuchulakanti PK. ARNI in cardiovascular disease: current evidence and future perspectives. Future Cardiol 2020; 16 (05) 505-515
    CrossrefPubMedGoogle Scholar
  • 81 Solomon SD, Claggett B, Desai AS. et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail 2016; 9 (03) e002744
    CrossrefPubMedGoogle Scholar
  • 82 Srivastava PK, Claggett BL, Solomon SD. et al. Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF Trial. JAMA Cardiol 2018; 3 (12) 1226-1231
    CrossrefPubMedGoogle Scholar
  • 83 Solomon SD, McMurray JJV, Anand IS. et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381 (17) 1609-1620
    CrossrefPubMedGoogle Scholar
  • 84 Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med 2022; 386 (21) 2024-2034
    CrossrefPubMedGoogle Scholar
  • 85 Martinez FA, Serenelli M, Nicolau JC. et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020; 141 (02) 100-111
    CrossrefPubMedGoogle Scholar
  • 86 Selvaraj S, Fu Z, Jones P. et al; DEFINE-HF Investigators. Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF. Circulation 2022; 146 (11) 808-818
    CrossrefPubMedGoogle Scholar
  • 87 Packer M, Anker SD, Butler J. et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383 (15) 1413-1424
    CrossrefPubMedGoogle Scholar
  • 88 Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987; 2 (8561): 709-711
    CrossrefPubMedGoogle Scholar
  • 89 Moss AJ, Hall WJ, Cannom DS. et al; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335 (26) 1933-1940
    CrossrefPubMedGoogle Scholar
  • 90 Moss AJ, Zareba W, Hall WJ. et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346 (12) 877-883
    CrossrefPubMedGoogle Scholar
  • 91 Kadish A, Dyer A, Daubert JP. et al; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350 (21) 2151-2158
    CrossrefPubMedGoogle Scholar
  • 92 Bardy GH, Lee KL, Mark DB. et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (03) 225-237
    CrossrefPubMedGoogle Scholar
  • 93 Abraham WT, Fisher WG, Smith AL. et al; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346 (24) 1845-1853
    CrossrefPubMedGoogle Scholar
  • 94 Bristow MR, Saxon LA, Boehmer J. et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350 (21) 2140-2150
    CrossrefPubMedGoogle Scholar
  • 95 Cleland JGF, Daubert J-C, Erdmann E. et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352 (15) 1539-1549
    CrossrefPubMedGoogle Scholar
  • 96 Malekan R, Lansman SL. Surgical treatment of heart failure in the elderly. Heart Fail Clin 2007; 3 (04) 501-509
    CrossrefPubMedGoogle Scholar
  • 97 Cleveland Jr JC, Grover FL, Fullerton DA. et al. Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival. J Thorac Cardiovasc Surg 2008; 136 (03) 774-777
    CrossrefPubMedGoogle Scholar
  • 98 Rose EA, Gelijns AC, Moskowitz AJ. et al; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345 (20) 1435-1443
    CrossrefPubMedGoogle Scholar
  • 99 Reardon S. First pig-to-human heart transplant: what can scientists learn?. Nature 2022; 601 (7893): 305-306
    CrossrefPubMedGoogle Scholar
  • 100 Reichart B, Längin M, Denner J, Schwinzer R, Cowan PJ, Wolf E. Pathways to clinical cardiac xenotransplantation. Transplantation 2021; 105 (09) 1930-1943
    CrossrefPubMedGoogle Scholar
  • 101 Padalino MA, Vida VL, Lo Rito M, Daliento L, Stellin G. The role of cardiac surgery in adult patients with congenital heart disease. J Cardiovasc Med (Hagerstown) 2013; 14 (05) 326-333
    CrossrefPubMedGoogle Scholar
  • 102 Smit-Fun VM, Buhre WF. Heart failure in adult patients with congenital heart disease. Anesthesiol Clin 2019; 37 (04) 751-768
    CrossrefPubMedGoogle Scholar
  • 103 Petrie MC, Jhund PS, She L. et al; STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016; 134 (18) 1314-1324
    CrossrefPubMedGoogle Scholar
  • 104 Howlett JG, Stebbins A, Petrie MC. et al; STICH Trial Investigators. CABG improves outcomes in patients with ischemic cardiomyopathy: 10-year follow-up of the STICH Trial. JACC Heart Fail 2019; 7 (10) 878-887
    CrossrefPubMedGoogle Scholar
  • 105 Davidson LJ, Davidson CJ. Transcatheter treatment of valvular heart disease: a review. JAMA 2021; 325 (24) 2480-2494
    CrossrefPubMedGoogle Scholar
  • 106 Lavall D, Hagendorff A, Schirmer SH, Böhm M, Borger MA, Laufs U. Mitral valve interventions in heart failure. ESC Heart Fail 2018; 5 (04) 552-561
    CrossrefPubMedGoogle Scholar
  • 107 Stone GW, Lindenfeld J, Abraham WT. et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379 (24) 2307-2318
    CrossrefPubMedGoogle Scholar
  • 108 Asmarats L, Puri R, Latib A, Navia JL, Rodés-Cabau J. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol 2018; 71 (25) 2935-2956
    PubMedGoogle Scholar
  • 109 Mehra MR, Uriel N, Naka Y. et al; MOMENTUM 3 Investigators. A fully magnetically levitated left ventricular assist device—final report. N Engl J Med 2019; 380 (17) 1618-1627
    CrossrefPubMedGoogle Scholar
  • 110 Molina EJ, Shah P, Kiernan MS. et al. The society of thoracic surgeons INTERMACS 2020 annual report. Ann Thorac Surg 2021; 111 (03) 778-792
    CrossrefPubMedGoogle Scholar
  • 111 Salerno CT, Hayward C, Hall S. et al; HeartWare HVAD System to HeartMate 3 Left Ventricular Assist System Device Exchange Advisory Group. HVAD to heartmate 3 left ventricular assist device exchange: best practices recommendations. Ann Thorac Surg 2022; 113 (06) 1770-1777
    CrossrefPubMedGoogle Scholar
  • 112 Coyle L, Gallagher C, Kukla L. et al. Two-year outcomes in HeartMate 3 versus HeartWare HVAD patients implanted as destination therapy. J Heart Lung Transplant 2020; 39 (04) S411
    CrossrefPubMedGoogle Scholar
  • 113 Lalonde SD, Alba AC, Rigobon A. et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg 2013; 28 (05) 604-610
    CrossrefPubMedGoogle Scholar
  • 114 Cook JA, Shah KB, Quader MA. et al. The total artificial heart. J Thorac Dis 2015; 7 (12) 2172-2180
    PubMedGoogle Scholar
  • 115 Baldetti L, Pagnesi M, Gramegna M. et al. Intra-aortic balloon pumping in acute decompensated heart failure with hypoperfusion: from pathophysiology to clinical practice. Circ Heart Fail 2021; 14 (11) e008527
    CrossrefPubMedGoogle Scholar
  • 116 Rock JR, Kos CA, Lemaire A. et al. Single center first year experience and outcomes with Impella 5.5 left ventricular assist device. J Cardiothorac Surg 2022; 17 (01) 124
    CrossrefPubMedGoogle Scholar
  • 117 Toda K, Ako J, Hirayama A. et al; J.-PVAD registry study investigators. Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD). J Artif Organs 2022; (e-pub ahead of print) DOI: 10.1007/s10047-022-01328-1.
    CrossrefPubMedGoogle Scholar
  • 118 Starling RC, Jessup M. Worldwide clinical experience with the CorCap cardiac support device. J Card Fail 2004; 10 (6, Suppl): S225-S233
    CrossrefPubMedGoogle Scholar
  • 119 Agdamag AC, Shaffer A, John R. et al. First successful LVAD implantation after bioventrix revivent TC ventricular reshaping. Ann Thorac Surg 2021; 112 (02) e123-e126
    CrossrefPubMedGoogle Scholar
  • 120 Dumcius A, Chekanov V, Vysockas V. Current status of cardiomyoplasty as surgical alternative for end-stage heart failure. Medicina (Kaunas) 2003; 39 (09) 815-822
    PubMedGoogle Scholar
  • 121 Abe T, Fukada J, Morishita K. The Batista procedure: fact, fiction and its role in the management of heart failure. Heart Fail Rev 2001; 6 (03) 195-199
    CrossrefPubMedGoogle Scholar
  • 122 Michler RE. Stem cell therapy for heart failure. Cardiol Rev 2014; 22 (03) 105-116
    CrossrefPubMedGoogle Scholar
  • 123 Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis 2020; 11 (05) 349
    CrossrefPubMedGoogle Scholar
  • 124 Curfman G. Stem cell therapy for heart failure: an unfulfilled promise?. JAMA 2019; 321 (12) 1186-1187
    CrossrefPubMedGoogle Scholar
  • 125 Anversa P, Kajstura J, Rota M, Leri A. Regenerating new heart with stem cells. J Clin Invest 2013; 123 (01) 62-70
    CrossrefPubMedGoogle Scholar